<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2025//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_250101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">37249280</PMID><DateCompleted><Year>2023</Year><Month>05</Month><Day>31</Day></DateCompleted><DateRevised><Year>2024</Year><Month>09</Month><Day>18</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">2050-4527</ISSN><JournalIssue CitedMedium="Internet"><Volume>11</Volume><Issue>5</Issue><PubDate><Year>2023</Year><Month>May</Month></PubDate></JournalIssue><Title>Immunity, inflammation and disease</Title><ISOAbbreviation>Immun Inflamm Dis</ISOAbbreviation></Journal><ArticleTitle>Efficacy of diet restriction with or without probiotic for treatment of patients with IBS-D: Phase I-II clinical trial.</ArticleTitle><Pagination><StartPage>e857</StartPage><MedlinePgn>e857</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">e857</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1002/iid3.857</ELocationID><Abstract><AbstractText Label="BACKGROUND AND AIM">Diet is a major contributor to irritable bowel syndrome (IBS) and is also a powerful tool for treatment of IBS. This study compared two diets and explored the effectiveness of the diets when combined with a probiotic for treatment of IBS-D patients.</AbstractText><AbstractText Label="METHODS">Phase I, patients were randomized into groups; control, cold/spicy/fried restricted diet (CSF res diet), IgG positive restricted diet (IgG res diet), and a combination both diets (CSF&#x2009;+&#x2009;IgG res diet). Phase II, patients were randomized into IgG res diet&#x2009;+&#x2009;placebo and IgG res diet + probiotic. Both interventions were 12 weeks in duration. Symptom Severity Scale (IBS-D-SSS) and IgG titer were assessed at the beginning and the end of the study.</AbstractText><AbstractText Label="RESULTS">Totals of 214 and 167 patients completed the two parts of the study, respectively. After intervention, IBS-D-SSS and TIgG grade were significantly improved compared to baseline, with results similar to the control group. In general, there were decreases in IBS-D-SSS and TIgG grade that were significantly different among the groups. There were exceptions; no differences were observed for IBS-D-SSS between the IgG res diet and CSF&#x2009;+&#x2009;IgG res diet, or TIgG grade between the CSF res diet, IgG res diet, and CSF&#x2009;+&#x2009;IgG res diet. However, the CSF res diet and IgG res diet had a synergistic effect that decreased IBS-D-SSS and TIgG titer, with a greater contribution by the IgG res diet. Therefore, we evaluated the IgG res diet with either placebo or probiotic and found that IBS-D-SSS and TIgG grade decreased from baseline. There was a significant decrease in IBS-D-SSS with the probiotic but TIgG grade was not significantly different between the IgG diet&#x2009;+&#x2009;placebo and IgG diet&#x2009;+&#x2009;probiotic diet.</AbstractText><AbstractText Label="CONCLUSIONS">Both the CSF res diet and IgG res diet improved IBS symptoms and demonstrated synergy, although the IgG res diet had a greater contribution. Further, when intolerant foods cannot be eliminated from a diet, avoiding uncooked, cold, spicy, fried, and alcoholic foods is a superior choice. The IgG res diet combined with Bifidobacteria was the best dietary choice and may function though a non-IgG pathway.</AbstractText><CopyrightInformation>&#xa9; 2023 The Authors. Immunity, Inflammation and Disease published by John Wiley &amp; Sons Ltd.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Zhao</LastName><ForeName>Xian-Shu</ForeName><Initials>XS</Initials><AffiliationInfo><Affiliation>Health Center of Screening and Prevention of Diseases, First Affiliated Hospital of Harbin Medical University, Harbin, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shi</LastName><ForeName>Li-Jun</ForeName><Initials>LJ</Initials><AffiliationInfo><Affiliation>Department of gastroenterology, First Affiliated Hospital of Harbin Medical University, Harbin, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ning</LastName><ForeName>Bao-Li</ForeName><Initials>BL</Initials><AffiliationInfo><Affiliation>Health Center of Screening and Prevention of Diseases, First Affiliated Hospital of Harbin Medical University, Harbin, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhao</LastName><ForeName>Zhi-Ming</ForeName><Initials>ZM</Initials><AffiliationInfo><Affiliation>Health Center of Screening and Prevention of Diseases, First Affiliated Hospital of Harbin Medical University, Harbin, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Xiao-Xue</ForeName><Initials>XX</Initials><AffiliationInfo><Affiliation>Department of gastroenterology, First Affiliated Hospital of Harbin Medical University, Harbin, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhu</LastName><ForeName>Meng-Hua</ForeName><Initials>MH</Initials><AffiliationInfo><Affiliation>Department of gastroenterology, First Affiliated Hospital of Harbin Medical University, Harbin, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Ya-Bing</ForeName><Initials>YB</Initials><AffiliationInfo><Affiliation>Department of gastroenterology, First Affiliated Hospital of Harbin Medical University, Harbin, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fu</LastName><ForeName>Jun</ForeName><Initials>J</Initials><Identifier Source="ORCID">0000-0002-7946-4208</Identifier><AffiliationInfo><Affiliation>Health Center of Screening and Prevention of Diseases, First Affiliated Hospital of Harbin Medical University, Harbin, China.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Immun Inflamm Dis</MedlineTA><NlmUniqueID>101635460</NlmUniqueID><ISSNLinking>2050-4527</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D043183" MajorTopicYN="Y">Irritable Bowel Syndrome</DescriptorName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011788" MajorTopicYN="N">Quality of Life</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019936" MajorTopicYN="Y">Probiotics</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004032" MajorTopicYN="N">Diet</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012720" MajorTopicYN="N">Severity of Illness Index</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Bifidobacteria</Keyword><Keyword MajorTopicYN="N">IBS-SSS</Keyword><Keyword MajorTopicYN="N">IgG antibody titers</Keyword><Keyword MajorTopicYN="N">diarrhea-predominant irritable bowel syndrome</Keyword><Keyword MajorTopicYN="N">probiotic</Keyword><Keyword MajorTopicYN="N">restricted diet</Keyword></KeywordList><CoiStatement>The authors declare no conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="revised"><Year>2023</Year><Month>3</Month><Day>26</Day></PubMedPubDate><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>8</Month><Day>3</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>4</Month><Day>21</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>5</Month><Day>31</Day><Hour>6</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>5</Month><Day>30</Day><Hour>13</Hour><Minute>7</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>5</Month><Day>30</Day><Hour>8</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2023</Year><Month>5</Month><Day>8</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37249280</ArticleId><ArticleId IdType="pmc">PMC10165954</ArticleId><ArticleId IdType="doi">10.1002/iid3.857</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Agr&#xe9;us L, Sv&#xe4;rdsudd K, Nyr&#xe9;n O, Tibblin G. Irritable bowel syndrome and dyspepsia in the general population: overlap and lack of stability over time. Gastroenterology. 1995;109(3):671&#x2010;680.</Citation><ArticleIdList><ArticleId IdType="pubmed">7657095</ArticleId></ArticleIdList></Reference><Reference><Citation>Jones R, Lydeard S. Irritable bowel syndrome in the general population. BMJ. 1992;304(6819):87&#x2010;90.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1880997</ArticleId><ArticleId IdType="pubmed">1737146</ArticleId></ArticleIdList></Reference><Reference><Citation>Wilson S, Roberts L, Roalfe A, Bridge P, Singh S. Prevalence of irritable bowel syndrome: a community survey. British J Gene Pract. 2004;54(504):495&#x2010;502.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1324800</ArticleId><ArticleId IdType="pubmed">15239910</ArticleId></ArticleIdList></Reference><Reference><Citation>Quigley EMM, Locke GR, Mueller&#x2010;Lissner S, et al. Prevalence and management of abdominal cramping and pain: a multinational survey. Aliment Pharmacol Ther. 2006;24(2):411&#x2010;419.</Citation><ArticleIdList><ArticleId IdType="pubmed">16842469</ArticleId></ArticleIdList></Reference><Reference><Citation>Everhart JE, Renault PF. Irritable bowel syndrome in office&#x2010;based practice in the United States. Gastroenterology. 1991;100(4):998&#x2010;1005.</Citation><ArticleIdList><ArticleId IdType="pubmed">2001837</ArticleId></ArticleIdList></Reference><Reference><Citation>Halpert A, Drossman D. Gender and irritable bowel syndrome: the male connection. J Clin Gastroenterol. 2004;38(7):546&#x2010;548.</Citation><ArticleIdList><ArticleId IdType="pubmed">15232355</ArticleId></ArticleIdList></Reference><Reference><Citation>Gralnek IM, Hays RD, Kilbourne A, Naliboff B, Mayer EA. The impact of irritable bowel syndrome on health&#x2010;related quality of life. Gastroenterology. 2000;119(3):654&#x2010;660.</Citation><ArticleIdList><ArticleId IdType="pubmed">10982758</ArticleId></ArticleIdList></Reference><Reference><Citation>Ringel Y, Maharshak N. Intestinal microbiota and immune function in the pathogenesis of irritable bowel syndrome. Am J Physiol Gastrointest Liver Physiol. 2013;305(8):G529&#x2010;G541.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3798736</ArticleId><ArticleId IdType="pubmed">23886861</ArticleId></ArticleIdList></Reference><Reference><Citation>Masuy I, Pannemans J, Tack J. Irritable bowel syndrome: diagnosis and management. Minerva Gastroenterol Dietol. 2020;66(2):136&#x2010;150.</Citation><ArticleIdList><ArticleId IdType="pubmed">31820883</ArticleId></ArticleIdList></Reference><Reference><Citation>El&#x2010;Salhy M, Gundersen D. Diet in irritable bowel syndrome. Nutr J. 2015;14:36.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4436161</ArticleId><ArticleId IdType="pubmed">25880820</ArticleId></ArticleIdList></Reference><Reference><Citation>B&#xf6;hn L, St&#xf6;rsrud S, T&#xf6;rnblom H, Bengtsson U, Simr&#xe9;n M. Self&#x2010;reported food&#x2010;related gastrointestinal symptoms in IBS are common and associated with more severe symptoms and reduced quality of life. Am J Gastroenterol. 2013;108(5):634&#x2010;641.</Citation><ArticleIdList><ArticleId IdType="pubmed">23644955</ArticleId></ArticleIdList></Reference><Reference><Citation>Bhat K, Harper A, Gorard DA. Perceived food and drug allergies in functional and organic gastrointestinal disorders. Aliment Pharmacol Ther. 2002;16(5):969&#x2010;973.</Citation><ArticleIdList><ArticleId IdType="pubmed">11966506</ArticleId></ArticleIdList></Reference><Reference><Citation>B&#xf6;hn L, St&#xf6;rsrud S, Simr&#xe9;n M. Nutrient intake in patients with irritable bowel syndrome compared with the general population. Neurogastroenterol Motility. 2013;25(1):23&#x2010;e1.</Citation><ArticleIdList><ArticleId IdType="pubmed">22937900</ArticleId></ArticleIdList></Reference><Reference><Citation>Galica AN, Galica R, Dumitra&#x219;cu DL. Diet, fibers, and probiotics for irritable bowel syndrome. J Med Life. 2022;15(2):174&#x2010;179.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8999090</ArticleId><ArticleId IdType="pubmed">35419092</ArticleId></ArticleIdList></Reference><Reference><Citation>Dimidi E, Whelan K. Food supplements and diet as treatment options in irritable bowel syndrome. Neurogastroenterol Motility. 2020;32(8):e13951.</Citation><ArticleIdList><ArticleId IdType="pubmed">32697018</ArticleId></ArticleIdList></Reference><Reference><Citation>Patel NV. Let food be thy Medicine&#x201d;: diet and supplements in irritable bowel syndrome. Clin Exp Gastroenterol. 2021;14:377&#x2010;384.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8473929</ArticleId><ArticleId IdType="pubmed">34588791</ArticleId></ArticleIdList></Reference><Reference><Citation>Manning LP, Yao CK, Biesiekierski JR. Therapy of IBS: is a low FODMAP diet the answer? Front Psychiatry. 2020;11:865.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7488954</ArticleId><ArticleId IdType="pubmed">33110411</ArticleId></ArticleIdList></Reference><Reference><Citation>Monsbakken KW, Vandvik PO, Farup PG. Perceived food intolerance in subjects with irritable bowel syndrome&#x2014;etiology, prevalence and consequences. Eur J Clin Nutr. 2006;60(5):667&#x2010;672.</Citation><ArticleIdList><ArticleId IdType="pubmed">16391571</ArticleId></ArticleIdList></Reference><Reference><Citation>Hill C, Guarner F, Reid G, et al. The international scientific association for probiotics and prebiotics consensus statement on the scope and appropriate use of the term probiotic. Nat Rev Gastroenterol Hepatol. 2014;11(8):506&#x2010;514.</Citation><ArticleIdList><ArticleId IdType="pubmed">24912386</ArticleId></ArticleIdList></Reference><Reference><Citation>Varsha KK, Maheshwari AP, Nampoothiri KM. Accomplishment of probiotics in human health pertaining to immunoregulation and disease control. Clin Nutri. 2021;44:26&#x2010;37.</Citation><ArticleIdList><ArticleId IdType="pubmed">34330476</ArticleId></ArticleIdList></Reference><Reference><Citation>Singh P, Lembo A. Emerging role of the gut microbiome in irritable bowel syndrome. Gastroenterol Clin North Am. 2021;50(3):523&#x2010;545.</Citation><ArticleIdList><ArticleId IdType="pubmed">34304786</ArticleId></ArticleIdList></Reference><Reference><Citation>Simon E, C&#x103;linoiu LF, Mitrea L, Vodnar DC. Probiotics, prebiotics, and synbiotics: implications and beneficial effects against irritable bowel syndrome. Nutrients. 2021;13(6):2112.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8233736</ArticleId><ArticleId IdType="pubmed">34203002</ArticleId></ArticleIdList></Reference><Reference><Citation>Van den Houte K, Colomier E, Schol J, Carbone F, Tack J. Recent advances in diagnosis and management of irritable bowel syndrome. Curr Opin Psychiatry. 2020;33(5):460&#x2010;466.</Citation><ArticleIdList><ArticleId IdType="pubmed">32639360</ArticleId></ArticleIdList></Reference><Reference><Citation>Guglielmetti S, Mora D, Gschwender M, Popp K. Randomised clinical trial: bifidobacterium bifidum MIMBb75 significantly alleviates irritable bowel syndrome and improves quality of life&#x2014;a double&#x2010;blind, placebo&#x2010;controlled study. Aliment Pharmacol Ther. 2011;33(10):1123&#x2010;1132.</Citation><ArticleIdList><ArticleId IdType="pubmed">21418261</ArticleId></ArticleIdList></Reference><Reference><Citation>Xie CR, Tang B, Shi YZ, et al. Low FODMAP diet and probiotics in irritable bowel syndrome: a systematic review with network meta&#x2010;analysis. Front Pharmacol. 2022;13:853011.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8959572</ArticleId><ArticleId IdType="pubmed">35355730</ArticleId></ArticleIdList></Reference><Reference><Citation>Ankersen DV, Weimers P, Bennedsen M, et al. Long&#x2010;term effects of a web&#x2010;based Low&#x2010;FODMAP diet versus probiotic treatment for irritable bowel syndrome, including shotgun analyses of microbiota: randomized, double&#x2010;crossover clinical trial. J Med Internet Res. 2021;23(12):e30291.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8715363</ArticleId><ArticleId IdType="pubmed">34904950</ArticleId></ArticleIdList></Reference><Reference><Citation>Hidalgo&#x2010;Cantabrana C, Delgado S, Ruiz L, Ruas&#x2010;Madiedo P, S&#xe1;nchez B, Margolles A. Bifidobacteria and their health&#x2010;promoting effects. Microbiology Spectrum . 2017;5(3). 10.1128/microbiolspec.BAD-0004-2016</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/microbiolspec.BAD-0004-2016</ArticleId><ArticleId IdType="pmc">PMC11687494</ArticleId><ArticleId IdType="pubmed">28643627</ArticleId></ArticleIdList></Reference><Reference><Citation>Sonnenburg JL, Chen CTL, Gordon JI. Genomic and metabolic studies of the impact of probiotics on a model gut symbiont and host. PLoS Biol. 2006;4(12):e413.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1661682</ArticleId><ArticleId IdType="pubmed">17132046</ArticleId></ArticleIdList></Reference><Reference><Citation>Monteagudo&#x2010;Mera A, Arthur JC, Jobin C, Keku T, Bruno&#x2010;Barcena JM, Azcarate&#x2010;Peril MA. High purity galacto&#x2010;oligosaccharides enhance specific Bifidobacterium species and their metabolic activity in the mouse gut microbiome. Beneficial Microbes. 2016;7(2):247&#x2010;264.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4974821</ArticleId><ArticleId IdType="pubmed">26839072</ArticleId></ArticleIdList></Reference><Reference><Citation>Carroccio A, Brusca I, Mansueto P, et al. A cytologic assay for diagnosis of food hypersensitivity in patients with irritable bowel syndrome. Clin Gastroenterol Hepatol. 2010;8(3):254&#x2010;260.</Citation><ArticleIdList><ArticleId IdType="pubmed">19932763</ArticleId></ArticleIdList></Reference><Reference><Citation>Buhner S, Li Q, Vignali S, et al. Activation of human enteric neurons by supernatants of colonic biopsy specimens from patients with irritable bowel syndrome. Gastroenterology. 2009;137(4):1425&#x2010;1434.</Citation><ArticleIdList><ArticleId IdType="pubmed">19596012</ArticleId></ArticleIdList></Reference><Reference><Citation>Volta U, De Giorgio R. New understanding of gluten sensitivity. Nat Rev Gastroenterol Hepatol. 2012;9(5):295&#x2010;299.</Citation><ArticleIdList><ArticleId IdType="pubmed">22371218</ArticleId></ArticleIdList></Reference><Reference><Citation>Volta U, Tovoli F, Cicola R, et al. Serological tests in gluten sensitivity (nonceliac gluten intolerance). J Clin Gastroenterol. 2012;46(8):680&#x2010;685.</Citation><ArticleIdList><ArticleId IdType="pubmed">22138844</ArticleId></ArticleIdList></Reference><Reference><Citation>Halmos EP, Power VA, Shepherd SJ, Gibson PR, Muir JG. A diet low in FODMAPs reduces symptoms of irritable bowel syndrome. Gastroenterology. 2014;146(1):67&#x2010;75.e5.</Citation><ArticleIdList><ArticleId IdType="pubmed">24076059</ArticleId></ArticleIdList></Reference><Reference><Citation>Yu SJ, Lee HS, Gung HJ, et al. Efficacy of a restrictive diet in irritable bowel syndrome: a systematic review and network meta&#x2010;analysis. Korean J Gastroenterol. 2022;80(1):6&#x2010;16.</Citation><ArticleIdList><ArticleId IdType="pubmed">35879058</ArticleId></ArticleIdList></Reference><Reference><Citation>Goyal O, Batta S, Nohria S, et al. Low fermentable oligosaccharide, disaccharide, monosaccharide, and polyol diet in patients with diarrhea&#x2010;predominant irritable bowel syndrome: a prospective, randomized trial. J Gastroenterol Hepatol. 2021;36(8):2107&#x2010;2115.</Citation><ArticleIdList><ArticleId IdType="pubmed">33464683</ArticleId></ArticleIdList></Reference><Reference><Citation>Algera JP, Demir D, T&#xf6;rnblom H, Nybacka S, Simr&#xe9;n M, St&#xf6;rsrud S. Low FODMAP diet reduces gastrointestinal symptoms in irritable bowel syndrome and clinical response could be predicted by symptom severity: a randomized crossover trial. Clin Nutr. 2022;41(12):2792&#x2010;2800.</Citation><ArticleIdList><ArticleId IdType="pubmed">36384081</ArticleId></ArticleIdList></Reference><Reference><Citation>Halmos EP, Christophersen CT, Bird AR, Shepherd SJ, Gibson PR, Muir JG. Diets that differ in their FODMAP content alter the colonic luminal microenvironment. Gut. 2015;64(1):93&#x2010;100.</Citation><ArticleIdList><ArticleId IdType="pubmed">25016597</ArticleId></ArticleIdList></Reference><Reference><Citation>Caponio GR, Celano G, Calabrese FM, et al. Evaluation of the effects of the tritordeum&#x2010;based diet compared to the Low&#x2010;FODMAPs diet on the fecal metabolome of IBS&#x2010;D patients: a preliminary investigation. Nutrients. 2022;14(21):4628.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9657445</ArticleId><ArticleId IdType="pubmed">36364888</ArticleId></ArticleIdList></Reference><Reference><Citation>Mazzawi T, Gundersen D, Hausken T, El&#x2010;Salhy M. Increased chromogranin a cell density in the large intestine of patients with irritable bowel syndrome after receiving dietary guidance. Gastroenterol Res Pract. 2015;2015:1&#x2010;8.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4397028</ArticleId><ArticleId IdType="pubmed">25918524</ArticleId></ArticleIdList></Reference><Reference><Citation>Mazzawi T, Hausken T, Gundersen D, El&#x2010;Salhy M. Dietary guidance normalizes large intestinal endocrine cell densities in patients with irritable bowel syndrome. Eur J Clin Nutr. 2016;70(2):175&#x2010;181.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4744244</ArticleId><ArticleId IdType="pubmed">26603880</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>